Acorda resubmits NDA for inhaled Parkinson’s disease therapy

Acorda Therapeutics (NSDQ:ACOR) said today that it resubmitted its new drug application for Inbrija, an inhaled therapy for people with Parkinson’s disease.

The Ardsley, N.Y.-based company was dealt a setback in August when the FDA told Acorda that it wouldn’t review its application for Inbrija, a move that sent ACOR shares tumbling.

Get the full story at our sister site, Drug Delivery Business News.

The post Acorda resubmits NDA for inhaled Parkinson’s disease therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2ABreqG